The Biotechnology Industry Organization (BIO) “applauded” passage of H.R. 475 to update the existing excise tax to cover the newest seasonal influenza vaccines under a no-fault compensation program for those injured by covered vaccines. Currently, the law which imposes the excise tax on seasonal influenza vaccines applies only to trivalent (3-strain) vaccines, and excludes any non-trivalent vaccines. In February, the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) selected the appropriate strains for the 2013-14 influenza season, including a fourth strain for quadrivalent vaccines. The first quadrivalent (4-strain) influenza vaccine was approved by the FDA in December 2012 and two other vaccines have been approved since that time. Without coverage by the VICP, the newest vaccines would not be as widely-available as otherwise.